The Garlic Shoppe, Gilroy

05/17/2026

Monarchs aren't the only orange butterflies out there!

Viceroys and queens are the most commonly confused monarch lookalikes, but even smaller butterflies like the red admiral or painted lady can fool people sometimes. Queen and soldier butterflies also use milkweed as a host plant and have similar-looking caterpillars to monarchs, so that can make things tricky as well.

Before you submit your first Journey North report of the season, check out this graphic to make sure you saw a monarch!

04/28/2026

For parents and grandparents that want to make their kids dream come true

04/25/2026

03/23/2026

🧠💡 Alzheimer's care just got a finish line. "Donanemab" clears amyloid plaque so thoroughly that nearly half of patients stopped treatment within a year while retaining benefits. No more lifelong dependency—just a finite clean-up mission.
From management to remission.

What does this potential breakthrough mean for families affected by Alzheimer's? Could this be a turning point?

Disclaimer: This content is for informational and educational purposes only.

03/23/2026

Tesla's FSD is proving to be significantly safer than human drivers, according to the latest data. Tesla FSD now records 5.3 million miles between accidents, compared to the US national driving average of just 660,000 miles between crashes. That makes FSD roughly 9 times safer than the average American driver on the road. The gap highlights just how far Tesla's autonomous driving software has come, and the numbers are only expected to improve as the system continues to learn from billions of miles of real-world driving data. While critics continue to question the safety of self-driving technology, Tesla's own data paints a clear picture that FSD-equipped vehicles are involved in far fewer accidents per mile than traditionally driven cars.

03/23/2026

History has been made. A global longevity biotech company received regulatory clearance in January 2026 to launch the world's first Phase 1 human trial testing a gene therapy designed to partially "reset" a cell's biological age. The therapy, called ER-100, uses partial epigenetic reprogramming — a method pioneered by Harvard-linked scientists — to restore youthful gene expression patterns in aging cells. The trial's initial target: glaucoma patients, where aging retinal cells lose function. Early animal data showed near-complete restoration of vision function within weeks of treatment.

The underlying theory, developed over a decade of research, is that aging is not irreversible wear-and-tear — it is a change in how DNA is chemically "programmed" over time, like software corruption that can be re-patched. By delivering a specific cocktail of reprogramming factors (Oct4, Sox2, Klf4) in a controlled way, the therapy partially rewinds a cell's epigenetic clock without triggering cancerous growth. If the human trial succeeds, the implications extend far beyond the eye: heart tissue, brain neurons, kidney cells — every organ in the body runs on the same aging clock. Humanity's first serious assault on aging itself has begun.